NEW YORK, Nov. 18 (GenomeWeb News) - Genaissance Pharmaceuticals today announced that it has licensed its HAP genotyping technology platform to consumer product biotech firm Sciona.
In exchange for the technology license, Genaissance obtained a 30 percent equity position in the privately traded UK-based company. Genaissance will receive royalties on any products Sciona develops using the HAP technology.
Kevin Rakin, president and CEO of Genaissance, called Sciona "a leader in the emerging market of integrating genetic variation into wellness products." The deal "continues the commercialization of our HAP technology in a variety of new markets," he added.